filgrastim
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | GRANIX | — | 2018-07-31 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | NEUPOGEN | — | 1994-06-15 – 2015-03-30 | fda.gov ↗ |
| Approved | EU (EMA) | Tevagrastim | — | 2008-09-15 | europa.eu ↗ |
| Approved | US (FDA) | NEUPOGEN | — | 1991-02-20 | fda.gov ↗ |
Trials 180 · started per year
Also used as a comparator or background therapy in 852 trials
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-08-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States tevapharm.com ↗ |
| 2018-07-20 | Pfizer | U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi) pfizer.com ↗ |
| 2015-09-03 | Novartis Pharmaceuticals | Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States novartis.com ↗ |
| 2015-03-06 | Novartis Pharmaceuticals | FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz novartis.com ↗ |
| 2015-01-07 | Novartis Pharmaceuticals | Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee novartis.com ↗ |
| 2014-12-23 | Teva Branded Pharmaceutical Products R&D, Inc. | FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration tevapharm.com ↗ |
| 2012-08-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia tevapharm.com ↗ |
Evidence & citations 48 cited values
Every value below carries the sentence it was read from. 1,037 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | filgrastim | “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗953“The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better...” NCT00103610 ↗ “granulocyte colony-stimulating factor (G-CSF; filgrastim, Neupogen®) has been shown to shorten the duration of severe neutropenia, fever, antibiotic use and hospitalization...” NCT02282215 ↗ “Colony-stimulating factors, such as filgrastim-sndz, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover...” NCT00801489 ↗ “Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours...” NCT01704716 ↗ “The purpose of this pilot study is to evaluate the immunologic and the clinical response to granulocyte-colony stimulating factor (G-CSF, Filgrastim, Neupogen) administered to...” NCT00025805 ↗ “Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight...” NCT00003659 ↗ “A total of 170 lymphoma patients who are eligible are planned to randomized assigned into two groups to receive mecapegfilgrastim fixed dose of 6 mg or filgrastim 5 µg/kg/day...” NCT04460508 ↗ “As part of standard care, you will receive G-CSF (filgrastim) as an injection just under your skin 1 time a day starting on Day +5 until your blood cell levels return to normal.” NCT01421173 ↗ “Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan.” NCT02649673 ↗ “Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium.” NCT00629018 ↗ “Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim.” NCT03395028 ↗ “You will receive filgrastim as an injection under the skin 1 time a day, starting 1 week after the transplant, until your blood cell levels return to normal.” NCT01572662 ↗ “Patients receive azacitidine SC or IV on days 1-5 (week 1), darbepoetin alfa** SC on day 8 (week 2), and filgrastim (G-CSF) SC 3 times weekly in weeks 2-4.” NCT00398047 ↗ “All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.” NCT07188090 ↗ “In Canada, the only drug used to mobilize stem cells from donors is filgrastim, a form of granulocyte colony stimulating factor (G-CSF).” NCT01403896 ↗ “Patients may receive prophylactic pegfilgrastim on day 3 of each cycle, or filgrastim for 5 to 10 days, per investigator's discretion.” NCT01657331 ↗ “Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.” NCT05753618 ↗ “Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.” NCT05298358 ↗ “Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis.” NCT02676622 ↗ “autologous dendritic cell mobilization with filgrastim (G-CSF) and/or sargramostim (GM-CSF) subcutaneously daily for 4 days” NCT00088985 ↗ “The names of the non-investigational supportive care drugs are: * Filgrastim, pegfilgrastim, or a related growth factor.” NCT04661852 ↗ “In the event of febrile neutropenia or prolonged grade IV neutropenia, pegfilgrastim or filgrastim is given for treatment” NCT00256360 ↗ “Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.” NCT05790096 ↗ “Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1.” NCT02725086 ↗ “Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery” NCT00820976 ↗ “G-CSF (filgrastim): 5 micrograms per kilogram (μg/kg) per day subcutaneously (SC) or IV from day -1 to day 5.” NCT04240002 ↗ “Filgrastim or pegfilgrastim will be injected under the skin within 72 hours after each cycle of chemotherapy.” NCT00968253 ↗ “G-CSF (Filgrastim) administration - G-CSF will be given by injection under the skin daily for up to 10 days.” NCT00011830 ↗ “Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology.” NCT04558736 ↗ “FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously.” NCT00228813 ↗ “Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy.” NCT02356159 ↗ “Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5)” NCT06660368 ↗ “Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy” NCT00520130 ↗ “daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF” NCT00772122 ↗ “Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.” NCT00189137 ↗ “Filgrastim, a shorter active form of pegfilgrastim may be used instead or added later if needed” NCT00671658 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 9 and continuing until blood count recover” NCT00433433 ↗ “G-CSF is also called Filgrastim, and brand names include Granix®, Neupogen®, and Zarxio®.” NCT06649851 ↗ “GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim” NCT00658385 ↗ “after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days” NCT00730561 ↗ “All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).” NCT01501487 ↗ “Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells.” NCT01639690 ↗ “patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day.” NCT02805153 ↗ “G-CSF (filgrastim) which 'mobilize' them from the bone marrow into the bloodstream” NCT00234169 ↗ “granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim)” NCT00103662 ↗ “Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar” NCT02793544 ↗ “They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6” NCT00515138 ↗ “standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim)” NCT01513603 ↗ “filgrastim (G-CSF) subcutaneously (SC) twice daily on days -33 to -29” NCT00392691 ↗ “Granulocyte colony-stimulating factor (G-CSF), filgrastim (Neupogen®)” NCT02128230 ↗ “Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)” NCT01711073 ↗ “day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc” NCT01827605 ↗ “Intervention type : Drug Intervention name : G-CSF (Filgrastim)” NCT02427919 ↗ “G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously.” NCT04411212 ↗ “G-CSF (filgrastim) followed by infusional Taxol (paclitaxel)” NCT00001384 ↗ “Biosimilar filgrastim or Grastofil® (one dose for 5 days)” NCT06116734 ↗ “Filgrastim (or equivalent haematopoietic growth factor)” NCT04685616 ↗ “filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous” NCT03922724 ↗ “Filgrastim, 5 microgram/kg per day subcutaneous (SQ)” NCT01287104 ↗ “Filgrastim was given on days 2-7, 9-12, 18-21, 23-28” NCT00517894 ↗ “Filgrastim (G-CSF) injection under skin once daily” NCT00385788 ↗ “Filgrastim, Amgen, California, USA 300 mg/1.0 mL” NCT03945812 ↗ “reference product (filgrastim; US-Neupogen®)” PMID 30900158 ↗ Apr 2019 “Filgrastim (G-CSF) 5 mcg/kg IV q12 hours” NCT01182675 ↗ “KRN8601(filgrastim), PLR001(plerixafor)” NCT05007652 ↗ “Filgrastim biosimilars are permissible” NCT06859424 ↗ “Filgrastim or pegylated filgrastim” NCT00953420 ↗ “Filgrastim: 5 µg/kg/day on Day1-14” NCT05608148 ↗ “Other Names: Filgrastim Neupogen” NCT02809092 ↗ “filgrastim, pegfilgrastim” NCT04584112 ↗ “filgrastim or NeupogenR” NCT00363467 ↗ “Filgrastim, Lenograstim” NCT06145321 ↗ “NEUPOGEN (Filgrastim)” NCT01202643 ↗ “Filgrastim, Neupogen®” NCT02918292 ↗ “Leucostim®(Filgrastim” NCT03783208 ↗ “Neupogen, Filgrastim” NCT03018223 ↗ “G-CSF (Filgrastim)” NCT00592111 ↗ “Filgrastim (G-CSF)” NCT00450801 ↗ “Filgrastim” NCT01146834 ↗ “Filgrastim” NCT04154735 ↗ “Filgrastim” NCT03042780 ↗ “filgrastim” NCT01046825 ↗ “Filgrastim” NCT05520723 ↗ “Filgrastim” NCT00352027 ↗ “Filgrastim” NCT01161550 ↗ “Filgrastim” NCT01731886 ↗ “Filgrastim” NCT01065129 ↗ “Filgrastim” NCT02750254 ↗ “Filgrastim” NCT06528691 ↗ “filgrastim” NCT03125642 ↗ “filgrastim” NCT06007911 ↗ “filgrastim” NCT03646123 ↗ “filgrastim” NCT02703779 ↗ |
| Known as | AX200 | “Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy.” PMID 23963331 ↗ Aug 2013 |
| Known as | biosimilar filgrastim | “biosimilar filgrastim” NCT06116734 ↗ |
| Known as | Filgrastim (G-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03263936 ↗ |
| Known as | Filgrastim Hospira | “the proposed biosimilar Filgrastim Hospira (US) and the US-approved Neupogen reference product” NCT02923791 ↗ |
| Known as | Filgrastim Megalabs | “Filgrastim Megalabs injectable 5 μg/Kg/day in a single subcutaneous application during 5 days” NCT04958772 ↗ |
| Known as | Filgrastim, Neupogen | “Filgrastim, Neupogen®” NCT02918292 ↗ |
| Known as | filgrastim-aafi | “PF-06881893 (filgrastim-aafi; Nivestym™), a filgrastim biosimilar” PMID 30900158 ↗ Apr 2019 |
| Known as | Filgrastim-sndz | “filgrastim-sndz” NCT02703779 ↗ |
| Known as | filigrastin | “The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days” NCT00213759 ↗ |
| Known as | G-colony stimulating factor | “Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).” NCT04179929 ↗ |
| Known as | G-CSF | “The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better...” NCT00103610 ↗172“Patients receive cytoreduction and mobilization of peripheral blood stem cells (PBSC) with filgrastim (G-CSF) and cyclophosphamide/paclitaxel, cyclophosphamide/etoposide or...” NCT00002977 ↗ “After an initial harvest of filgrastim (G-CSF)-mobilized autologous peripheral blood stem cells (PBSC) for transplantation, patients receive one additional dose of G-CSF and...” NCT00006225 ↗ “The purpose of this pilot study is to evaluate the immunologic and the clinical response to granulocyte-colony stimulating factor (G-CSF, Filgrastim, Neupogen) administered to...” NCT00025805 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 2 days after completion of cyclophosphamide and continuing until autologous peripheral blood stem cells...” NCT00002680 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 4 days prior to peripheral blood stem cell (PBSC) collection and continuing until the target number of...” NCT00020410 ↗ “Beginning at least 4 weeks prior to the start of chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily until the completion of peripheral blood stem cell...” NCT00002601 ↗ “Patients also receive sargramostim (GM-CSF) subcutaneously (SC) alone on days 3-9 and GM-CSF and filgrastim (G-CSF) SC beginning on day 10 and continuing until leukapheresis is...” NCT00027937 ↗ “This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.” PMID 41510127 ↗ Dec 2025 “Patients receive filgrastim (G-CSF) subcutaneously (SC) beginning 4 days prior to peripheral blood stem cell (PBSC) mobilization and continuing until adequate PBSC are collected.” NCT00008021 ↗ “This study will compare the combination of meloxicam with a drug called G-CSF (also called neupogen), to the combination of G-CSF with an agent that has no medicine (placebo).” NCT02003625 ↗ “Patients in dose levels 5 and above also receive filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing for at least 7 days or until blood counts recover.” NCT00004212 ↗ “Patients then receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning 24 hours after completion of chemotherapy and continuing until blood counts recover.” NCT00019864 ↗ “Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.” NCT00003657 ↗ “Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim.” NCT03395028 ↗ “filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 10 and continuing until an adequate number of peripheral blood stem cells (PBSC) are collected.” NCT00242996 ↗ “Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg/day, to be discontinued when neutrophils recover and white blood cell count is ≥20,000/μL” NCT07514936 ↗ “Patients were also randomly assigned to receive filgrastim (G-CSF) from day 0 until neutrophil count was greater than 0.5 x 10(9)/L (or for a maximum of 28 days)” PMID 16484584 ↗ Feb 2006 “Filgrastim (G-CSF) is administered daily beginning 2 days after completion of ARA-C infusion and continuing until harvest of peripheral blood stem cells (PBSC).” NCT00003632 ↗ “Determine the efficacy of filgrastim (G-CSF) in preventing persistent moderate neutropenia in patients with solid tumors while maintaining chemotherapy courses.” NCT00770172 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) beginning 24 hours after completion of cyclophosphamide and continuing until leukapheresis is complete.” NCT00017641 ↗ “Patients also receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 5 of courses 3, 5, and 7 and continuing until blood counts recover.” NCT00024193 ↗ “Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.” NCT00003116 ↗ “Evaluate the efficacy of filgrastim (G-CSF) in preventing hematological toxicity in women with breast cancer receiving neoadjuvant or adjuvant chemotherapy.” NCT00771433 ↗ “Beginning 48 hours after the last dose of MTX, patients receive filgrastim (G-CSF)\* subcutaneously once daily for 7-10 days or until blood counts recover.” NCT00074178 ↗ “Patients receive docetaxel IV over 1 hour on day 1, vinorelbine IV over 6-10 minutes on days 8 and 15, and filgrastim (G-CSF) subcutaneously on days 2-21.” NCT00015938 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.” NCT00093483 ↗ “Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover.” NCT00028665 ↗ “Beginning on day 10, patients receive filgrastim (G-CSF) until the absolute neutrophil count is greater than 1,000/mm3 for 2 consecutive days.” NCT00004464 ↗ “Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy.” PMID 23963331 ↗ Aug 2013 “Patients also receive filgrastim (G-CSF) subcutaneously (SC) twice daily beginning on day 3 and continuing until leukapheresis is completed.” NCT00423852 ↗ “Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).” NCT04179929 ↗ “Patients receive filgrastim (G-CSF) IV over 1 hour OR subcutaneously daily beginning on day 28 and continuing until blood counts recover.” NCT00083135 ↗ “Patients receive filgrastim (G-CSF) subcutaneously daily beginning on day 0 and continuing until blood counts have recovered for 2 days.” NCT00004898 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 13 and continuing until blood counts recover.” NCT00040690 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 0 and continuing until 3 days after blood counts have recovered.” NCT00004174 ↗ “patients receive filgrastim (G-CSF) subcutaneously (SC) daily until the completion of peripheral blood stem cell (PBSC) harvesting.” NCT00017628 ↗ “then filgrastim (G-CSF) beginning 24 hours following completion of paclitaxel and continuing through the last day of leukapheresis” NCT00003392 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) or IV daily beginning on day 10 and continuing until blood counts recover.” NCT00003243 ↗ “stem cell mobilization comprising dexamethasone, carmustine, cytarabine, etoposide, melphalan (Dexa-BEAM), and filgrastim (G-CSF)” NCT00275015 ↗ “Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.” NCT05298358 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously once daily beginning on day 4 and continuing until blood counts recover.” NCT00274807 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) once a day beginning on day 5 and continuing until blood counts recover.” NCT00521014 ↗ “Participants in this study will receive a twice daily dose of Filgrastim (GCSF) (5 mcg/kg BID) SQ starting on day 1 for 5 days” NCT07585136 ↗ “followed by filgrastim (G-CSF) subcutaneously beginning on day 10 and continuing until a target number of cells are collected” NCT00012051 ↗ “Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 5 and continuing until blood counts recover.” NCT00004137 ↗ “To evaluate the safety and efficacy of filgrastim (G-CSF) in reducing grade 4 neutropenia or grades 3-4 febrile neutropenia” NCT00554463 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing until blood counts recover.” NCT00005958 ↗ “autologous dendritic cell mobilization with filgrastim (G-CSF) and/or sargramostim (GM-CSF) subcutaneously daily for 4 days” NCT00088985 ↗ “Patients in regimens A, B, and C undergo leukapheresis after receiving filgrastim (G-CSF) by subcutaneous (SC) injections.” NCT00003273 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover.” NCT00003311 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).” NCT00003567 ↗ “Filgrastim (G-CSF) IV or SC is administered beginning on day 0 and continuing for 21 days or until blood counts recover.” NCT00004132 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SQ) or IV beginning on day -5 and continuing through at least day 3.” NCT00005952 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) twice daily beginning on day 0 and continuing for up to 5 days.” NCT00091104 ↗ “Arm I: Patients receive docetaxel and doxorubicin once followed by filgrastim (G-CSF) daily for approximately 1 week.” NCT00012311 ↗ “Beginning one day after each treatment course, patients receive filgrastim (G-CSF) subcutaneously daily for 10 days.” NCT00004006 ↗ “Filgrastim (G-CSF) is administered subcutaneously beginning on day 2 and continuing until blood cell counts recover.” NCT00003860 ↗ “Patients receive daily filgrastim (G-CSF) subcutaneously for 4 days until peripheral blood stem cells are collected.” NCT00003400 ↗ “An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.” NCT02739295 ↗ “Beginning 1-2 days after lymphocyte administration, patients receive filgrastim (G-CSF) subcutaneously (SC) daily” NCT00062036 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts recover.” NCT00296023 ↗ “Patients receive interleukin-11 (IL-11) subcutaneously (SQ) on days 1-10 and filgrastim (G-CSF) SQ on days 4-10.” NCT00004157 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.” NCT00054236 ↗ “filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 3 and continuing until blood counts recover” NCT00025324 ↗ “The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days” NCT00213759 ↗ “G-CSF (Filgrastim) administration - G-CSF will be given by injection under the skin daily for up to 10 days.” NCT00011830 ↗ “Patients receive filgrastim (G-CSF) IV once daily for 6 days followed by a maximum of 5 apheresis sessions.” NCT00053118 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy” NCT00002611 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy” NCT00002610 ↗ “Patients also receive filgrastim (G-CSF) IV beginning on day 0 and continuing until blood counts recover.” NCT00007891 ↗ “patients with low neutrophil counts receive filgrastim (G-CSF) subcutaneously until blood count recovers.” NCT00293319 ↗ “All patients receive filgrastim (G-CSF) IV beginning on day 1 and continuing until blood counts recover.” NCT00290628 ↗ “and filgrastim (G-CSF) subcutaneously or IV starting on day 0 and continuing until blood counts recover.” NCT00005978 ↗ “filgrastim (G-CSF) subcutaneously (SC) beginning on day 9 and continuing until the last day of apheresis” NCT00052923 ↗ “filgrastim (G-CSF) IV beginning 4 hours after transplantation and continuing until blood counts recover” NCT00003913 ↗ “Filgrastim (G-CSF) is widely used for treatment of patients who have a deficiency of white blood cells.” NCT01617577 ↗ “filgrastim (G-CSF) subcutaneously (SC) starting on day 2 and continuing until the last day of apheresis” NCT00006390 ↗ “Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5)” NCT06660368 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 3 and until blood counts recover.” NCT00002675 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until completion of leukapheresis” NCT00003877 ↗ “filgrastim (G-CSF) subcutaneously (SC) beginning on day 17 and continuing until approximately day 25.” NCT00274794 ↗ “filgrastim (G-CSF) subcutaneously (SC) beginning on day 6 and continuing until blood counts recover” NCT00017368 ↗ “filgrastim (G-CSF) subcutaneously (SC) beginning on day 9 and continuing until blood counts recover” NCT00410631 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 1 until hematopoietic recovery.” NCT00006040 ↗ “filgrastim (G-CSF) subcutaneously (SC) beginning on day 6 and continuing until blood counts recover” NCT00080925 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) on days 7-16 or until blood counts recover.” NCT00002596 ↗ “Filgrastim (G-CSF) is administered subcutaneously (SC) on days 7-18 or until blood counts recover.” NCT00002559 ↗ “mobilization chemotherapy followed by filgrastim (granulocyte colony-stimulating factor; G-CSF).” NCT00002788 ↗ “Following transplantation, patients receive filgrastim (G-CSF) daily until blood counts recover.” NCT00008229 ↗ “filgrastim (G-CSF) subcutaneously (SC) starting day 11 and continuing until blood counts recover” NCT00002868 ↗ “Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization.” NCT00066092 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) followed by SCF SC daily for 7-10 days.” NCT00005993 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 9 and continuing until blood count recover” NCT00433433 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) daily for 4 days prior to apheresis” NCT00009763 ↗ “GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim” NCT00658385 ↗ “Assess filgrastim (G-CSF) support in the recovery phase after the first induction course” NCT00002658 ↗ “patients receive subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF).” NCT00003183 ↗ “filgrastim (G-CSF) subcutaneously once a day starting day -5 until blood counts recover” NCT00005852 ↗ “filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover” NCT00278408 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-6 or 1-7.” NCT00017355 ↗ “G-CSF (filgrastim) which 'mobilize' them from the bone marrow into the bloodstream” NCT00234169 ↗ “filgrastim (G-CSF) SQ beginning on day 0 and continuing until blood counts recover” NCT00004231 ↗ “filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.” NCT00077103 ↗ “All patients receive subcutaneous filgrastim (G-CSF) during stem cell collection.” NCT00003920 ↗ “filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover” NCT00010413 ↗ “Patients receive filgrastim (G-CSF) and then undergo apheresis for up to 5 days.” NCT00233961 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously (SC) daily on days 3-10.” NCT00014534 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover.” NCT00005964 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SC) twice daily on days 1-7.” NCT00005998 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing for 10 days” NCT00016341 ↗ “Donors receive filgrastim (G-CSF) subcutaneously once daily on days -4 to 0.” NCT00118326 ↗ “Patients receive filgrastim (G-CSF) subcutaneously twice daily on days 1-4” NCT00003927 ↗ “administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells” NCT00001071 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SQ) on days -11 to -7” NCT00004048 ↗ “granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim)” NCT00103662 ↗ “filgrastim (G-CSF) is administered subcutaneously (SC) on days -11 to -7” NCT00002600 ↗ “Patients receive filgrastim (G-CSF) subcutaneously daily for five days.” NCT00562640 ↗ “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous” NCT00821249 ↗ “Patients receive filgrastim (G-CSF) IV twice daily beginning on day 1.” NCT00002515 ↗ “Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4.” NCT00003398 ↗ “filgrastim (G-CSF) subcutaneously (SC) twice daily on days -33 to -29” NCT00392691 ↗ “filgrastim (recombinant granulocyte colony stimulating factor; G-CSF)” NCT00002255 ↗ “Patients also receive filgrastim (G-CSF) subcutaneously on days 4-13.” NCT00002866 ↗ “Patients receive filgrastim (G-CSF) subcutaneously daily on days 0-6” NCT00005896 ↗ “Patients receive filgrastim (G-CSF) subcutaneously daily for 5 days” NCT00004086 ↗ “Patients receive filgrastim (G-CSF) subcutaneously (SQ) on days 1-6” NCT00003792 ↗ “Patients also receive filgrastim (G-CSF) SC once daily on days 3-9.” NCT00392834 ↗ “Filgrastim (G-CSF) is administered subcutaneously starting on day 6” NCT00003388 ↗ “filgrastim (G-CSF) primed allogeneic peripheral blood stem cells” NCT00002832 ↗ “granulocyte colony-stimulating factor (G-CSF, A.K.A. Filgrastim)” NCT06174298 ↗ “Patients receive filgrastim (G-CSF) subcutaneously on days 8-14.” NCT00822120 ↗ “with filgrastim (G-CSF) and peripheral blood stem cell support” NCT00002948 ↗ “G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously.” NCT04411212 ↗ “Filgrastim (granulocyte-colony stimulating factor; G-CSF)” NCT00000801 ↗ “filgrastim (G-CSF) subcutaneously (SC) daily on days 1-7” NCT00002697 ↗ “filgrastim (G-CSF) subcutaneously (SC) or IV once daily” NCT00245115 ↗ “Patients receive filgrastim (G-CSF) on days -7 to -3” NCT00477971 ↗ “filgrastim (G-CSF) subcutaneously beginning on day 3” NCT00002501 ↗ “Filgrastim (G-CSF) injection under skin once daily” NCT00385788 ↗ “filgrastim (G-CSF) SC 3 times weekly in weeks 2-4.” NCT00398047 ↗ “filgrastim (G-CSF) subcutaneously daily for 4 days” NCT00004165 ↗ “filgrastim (G-CSF) subcutaneously (SC) once daily” NCT00079144 ↗ “filgrastim (G-CSF) subcutaneously (SC) once daily” NCT00028860 ↗ “filgrastim (G-CSF) subcutaneously on days 3-13” NCT00002764 ↗ “filgrastim (G-CSF) subcutaneously on days 4-13” NCT00002539 ↗ “filgrastim (G-CSF) IV or subcutaneously daily” NCT00055653 ↗ “filgrastim (G-CSF) subcutaneously (SC) or IV” NCT00070200 ↗ “filgrastim (G-CSF) subcutaneously (SC) daily” NCT00064337 ↗ “filgrastim (G-CSF) (SC) daily on days 7-16” NCT00003027 ↗ “filgrastim (G-CSF) subcutaneously daily” NCT00004055 ↗ “filgrastim (G-CSF) subcutaneously (SC)” NCT00009750 ↗ “filgrastim (G-CSF) subcutaneously (SQ)” NCT00004177 ↗ “filgrastim (G-CSF) subcutaneously” NCT00417053 ↗ “filgrastim (G-CSF) by injection” NCT00003416 ↗ “addition of filgrastim (G-CSF)” NCT00020371 ↗ “filgrastim (G-CSF) from day 1” NCT00003270 ↗ “filgrastim (G-CSF)” NCT00002616 ↗ “G-CSF (Filgrastim)” NCT06890039 ↗ “filgrastim (G-CSF)” NCT00058461 ↗ “filgrastim (G-CSF)” NCT00006760 ↗ “filgrastim (G-CSF)” NCT00003541 ↗ “filgrastim (G-CSF)” NCT00049569 ↗ “filgrastim (G-CSF)” NCT00002489 ↗ “G-CSF (filgrastim)” NCT01908621 ↗ “G-CSF (filgrastim)” NCT02722733 ↗ “G-CSF/Filgrastim” NCT00168168 ↗ “G-CSF” NCT00049114 ↗ “G-CSF” NCT00063934 ↗ “G-CSF” NCT00003178 ↗ |
| Known as | G-CSF (Filgrastim) | “G-CSF (Filgrastim)” NCT00592111 ↗ |
| Known as | G-CSF (granulocyte-colony stimulating factor) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00068393 ↗ |
| Known as | G-CSF mobilized peripheral blood cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02587871 ↗ |
| Known as | GCSF (Growth colony stimulating factor) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001832 ↗ |
| Known as | Gracinᵀᴹ | “Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle.” NCT02685111 ↗ |
| Known as | Granix | “Granix” NCT04154735 ↗ |
| Known as | Granix (tbo-filgrastim) | “Granix (tbo-filgrastim)” NCT02282215 ↗ |
| Known as | Granulocyte colony-stimulating factor | “Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy.” PMID 23963331 ↗ Aug 20137“mobilization chemotherapy followed by filgrastim (granulocyte colony-stimulating factor; G-CSF).” NCT00002788 ↗ “using granulocyte-colony stimulating factor (otherwise known as Filgrastim) with plerixafor” NCT07585136 ↗ “patients receive subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF).” NCT00003183 ↗ “granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim)” NCT00103662 ↗ “granulocyte colony-stimulating factor (G-CSF, A.K.A. Filgrastim)” NCT06174298 ↗ “Filgrastim (granulocyte-colony stimulating factor; G-CSF)” NCT00000801 ↗ “Granulocyte colony-stimulating factor (Filgrastim)” NCT02814110 ↗ |
| Known as | Granulocyte colony-stimulating factor (G-CSF), filgrastim (Neupogen) | “Granulocyte colony-stimulating factor (G-CSF), filgrastim (Neupogen®)” NCT02128230 ↗ |
| Known as | Granulocyte-colony stimulating factor (G-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01767714 ↗ |
| Known as | Granulokine | “Filgrastim (Granulokine, Amgen)” NCT01079676 ↗ |
| Known as | Grastofil | “Biosimilar filgrastim or Grastofil® (one dose for 5 days)” NCT06116734 ↗ |
| Known as | hrG-CSF | “Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)” NCT01102699 ↗ |
| Known as | KRN8601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007652 ↗ |
| Known as | Leucostim | “Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1.” NCT02725086 ↗ |
| Known as | leukostim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01571518 ↗ |
| Known as | Neupogen | “Filgrastim is a recombinant human G-CSF (rhG-CSF) developed in the mid 1980s, and was approved by the United States (US) Food and Drug Administration (FDA) for use in...” NCT00497809 ↗35“The purpose of this pilot study is to evaluate the immunologic and the clinical response to granulocyte-colony stimulating factor (G-CSF, Filgrastim, Neupogen) administered to...” NCT00025805 ↗ “This study will compare the combination of meloxicam with a drug called G-CSF (also called neupogen), to the combination of G-CSF with an agent that has no medicine (placebo).” NCT02003625 ↗ “Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)” NCT00794261 ↗ “Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1.” NCT02725086 ↗ “An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.” NCT02739295 ↗ “Patients will receive hematopoietic growth factor support with either Leukine (Arm A), or Neupogen (Arm B).” NCT00237575 ↗ “FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously.” NCT00228813 ↗ “recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland)” NCT00596479 ↗ “Before the transplant the research participant will receive daily G-CSF (Neupogen) for 5-6 days.” NCT00058578 ↗ “Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization.” NCT00066092 ↗ “GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim” NCT00658385 ↗ “ASCT,Rituxan, Ifex, Paraplatin®, etoposide, Vepesid®, Mesnex®, Neupogen, Neulasta” NCT00588094 ↗ “granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim)” NCT00207792 ↗ “Filgrastim (Neupogen) will be given prophylactically on day 5.” NCT01523678 ↗ “Other Names: Filgrastim Neupogen” NCT02809092 ↗ “Neupogen/Days 1-6” NCT00594555 ↗ “Neupogen” NCT04154735 ↗ “NEUPOGEN” NCT02703779 ↗ |
| Known as | Neupogen (filgrastim) | “Neupogen (filgrastim)” NCT02282215 ↗1“NEUPOGEN (Filgrastim)” NCT01202643 ↗ |
| Known as | NEUPOGEN (R) | “ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination” NCT00400556 ↗ |
| Known as | Neupogen(Registered) | “Multiple Subcutaneous (SC) Doses Of "Filgrastim Hospira" (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers” NCT02923791 ↗ |
| Known as | Nivestym | “PF-06881893 (filgrastim-aafi; Nivestym™), a filgrastim biosimilar” PMID 30900158 ↗ Apr 2019 |
| Known as | NSC-614629 | “Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗ |
| Known as | PF-06881893 | “PF-06881893 (filgrastim-aafi; Nivestym™), a filgrastim biosimilar” PMID 30900158 ↗ Apr 2019 |
| Known as | Post-Transplant G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06412497 ↗ |
| Known as | r-met HuG-CSF | “Frequently, Filgrastim (r-met HuG-CSF) is administrated alone; however, Filgrastim combined with chemotherapy has proven more effective in context of CD34+ cell numbers harvested” NCT01016795 ↗ |
| Known as | Recombinant Granulocyte Colony-Stimulating Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03670966 ↗ |
| Known as | recombinant human granulocyte colony-stimulating factor | “This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.” PMID 41510127 ↗ Dec 20255“Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle.” NCT03251768 ↗ “Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg/day, to be discontinued when neutrophils recover and white blood cell count is ≥20,000/μL” NCT07514936 ↗ “Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10\^9/L;” NCT04541277 ↗ “Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is an effective drug for the treatment of chemotherapy-induced neutropenia.” NCT02996617 ↗ |
| Known as | rG-CSF | “recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland)” NCT00596479 ↗ |
| Known as | rhG-CSF | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 202520“enteral recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO) in preventing feeding intolerance” PMID 25155966 ↗ Aug 2014 “Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion” NCT00776165 ↗ “Filgrastim(rhG-CSF, TOPNEUTER)” NCT01238562 ↗ “rhG-CSF” NCT03670966 ↗ |
| Known as | Tbo-filgrastim | “In retrospective studies, stem cell mobilization with tbo-filgrastim has shown similar efficacy and toxicity as filgrastim, but no prospective studies have been published to date.” PMID 28797783 ↗ Aug 20175“Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim.” NCT05780879 ↗ “Granix (tbo-filgrastim)” NCT02282215 ↗ |
| Known as | Topneuter | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 20251“Filgrastim(rhG-CSF, TOPNEUTER)” NCT01238562 ↗ |
| Known as | US-Approved Neupogen | “the proposed biosimilar Filgrastim Hospira (US) and the US-approved Neupogen reference product” NCT02923791 ↗ |
| Known as | US-Neupogen | “reference product (filgrastim; US-Neupogen®)” PMID 30900158 ↗ Apr 2019 |
| Known as | Zarxio | “Zarxio” NCT00801489 ↗ |
| Modality | Protein / enzyme biologic | “filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor; G-CSF )” NCT00002126 ↗ |
| Route | Subcutaneous | “GCSF will be administered subcutaneously at a dose of 5mcg/kg/day” NCT00001832 ↗ |